Compare AMSS & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMSS | MBIO |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 4.1M |
| IPO Year | 2026 | 2023 |
| Metric | AMSS | MBIO |
|---|---|---|
| Price | $0.24 | $0.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 62.0K | 36.8K |
| Earning Date | 11-16-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.99 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.71 | N/A |
| Revenue Next Year | $20.00 | $405.45 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $0.35 |
| 52 Week High | $2.44 | $1.44 |
| Indicator | AMSS | MBIO |
|---|---|---|
| Relative Strength Index (RSI) | 29.50 | 45.60 |
| Support Level | N/A | $0.35 |
| Resistance Level | $0.39 | $0.43 |
| Average True Range (ATR) | 0.04 | 0.03 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 18.97 | 64.93 |
Amass Brands Inc is building a diversified premium beverage platform at the intersection of craft, wellness, and functionality. The company operates in the beverage industry, offering a portfolio that includes spirits, wine, and non-alcoholic products. The company distributes its brands in the United States through wholesale, on-premise, and direct-to-consumer channels. The company has two segments: Wine and Spirits. The majority of the company's revenue is derived from the Wine segment, which offers a portfolio of premium imported and domestic wine brands. Geographically, it operates predominantly in the USA.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.